Vaxcyte Posts $297M Q3 Loss, $3.4B Pro Forma Cash, OPUS-2/3 Data in 1H 2027
PCVX sits 65% above its 52-week low of $39.87.
Summary
Vaxcyte reported a $297.1 million Q3 net loss on higher R&D and put pro forma cash at about $3.4 billion after its October offerings. OPUS-2 and OPUS-3 data are now guided to the first half of 2027, with a BLA planned for the first half of 2028.
Key Events · Earnings and Guidance · PCVX
-
Q3 Loss Widens on R&D Spend
Net loss was $297.1 million ($1.99 per share) versus $212.8 million ($1.56) a year earlier, as R&D rose to $270.3 million from $209.9 million.
-
Pro Forma Cash of ~$3.4 Billion
Cash and investments were $2,264.4 million at September 30, 2026; adding the approximately $1.1 billion in October net proceeds gives pro forma liquidity of about $3.4 billion.
-
OPUS-2/3 Data Guided to 1H 2027
Both fully enrolled Phase 3 trials are now expected to report in the first half of 2027, supporting a planned BLA submission in the first half of 2028.
-
Infant and VAX-A1 Timelines Set
VAX-31 infant Phase 2 topline data are expected by the end of the first half of 2027, and VAX-A1 Phase 1 is advancing to Stage 2 after a DSMB safety review.
Analysis · PCVX · Life Sciences
The quarter itself is a cash-burn story: R&D jumped to $270.3 million from $209.9 million and the net loss widened to $297.1 million from $212.8 million. What matters more is the runway. Roughly $1.1 billion of October net proceeds lifts pro forma cash to about $3.4 billion, which management says funds a potential U.S. adult launch of VAX-31 plus the remaining Phase 3 work. The timeline is now explicit: OPUS-2 and OPUS-3 read out in the first half of 2027, and the BLA is planned for the first half of 2028. That pushes the next binary catalyst roughly six to nine months out, so near-term the stock trades on execution and spending rather than new data.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCVX was trading at $65.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3B. The 52-week trading range was $39.87 to $90.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.